Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tideglusib (Primary)
Indications Myotonic dystrophy
Focus Adverse reactions; Therapeutic Use
Acronyms REACH CDM X
Sponsors AMO Pharma

Most Recent Events

28 May 2025 Planned End Date changed from 28 Mar 2025 to 31 Dec 2026.
28 May 2025 Planned primary completion date changed from 28 Mar 2025 to 31 Dec 2026.
23 May 2023 Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) has ben newly added as a primary end-point, thus making "TU" also a trial focus. Timeline for safety end-point is increased from 54 to 86 weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com